Aspirin for prevention of cardiovascular disease in patients with high levels of lipoprotein(a): Evidence from two-sample Mendelian randomization analysis

J Evid Based Med. 2023 Dec;16(4):432-434. doi: 10.1111/jebm.12562. Epub 2023 Dec 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aspirin / therapeutic use
  • Cardiovascular Diseases* / prevention & control
  • Humans
  • Lipoprotein(a)
  • Mendelian Randomization Analysis
  • Risk Factors

Substances

  • Lipoprotein(a)
  • Aspirin